Centre for Cell Therapy and Translation (C2T2)
C2T2 provides a cutting-edge pre-clinical assessment unit, focused on cell-based therapies, that will bridge the ”translation gap”.
Overview
The C2T2 pipeline is an essential connection between new therapies (UofC, other Universities and Industry) to GMP facilities (ACTM, CellCAN, CCRM) or clinical laboratories (Cell Therapy Lab at APL). C2T2 enables translation and commercialization of these technologies through cell biology/characterization, bio-processing/scale-up and large animal models. Projects conducted at C2T2 benefit from the integration of all three aspects.
By capitalizing on our multidisciplinary expertise (veterinary medicine, stem cell biology, biomedial engineering) C2T2 and its partners will enable more effective evaluation and translation of regenerative therapeutics, including cell-based therapies.
C2T2 will transform Canada’s stem cell research effort by serving as a North American hub for pre-clinical translation of cell therapies (which will also include evaluation of biologics, pharmaceuticals, or medical devices).
C2T2 fosters
- Intellectual and financial investment
- Creation of emergent knowledge
- Training highly qualified personnel (across disciplines)
- Generate new commercialization opportunities
- Commercial value will be realized in potential medical and veterinary applications (companion animals and performance horses)